Dronabinol does not cause metabolic disturbances in managing chronic neuropathy pain
A 4-week pilot study with the cannabinoid receptor agonist dronabinol and its effect on metabolic parameters in a randomized trialClin Ther. 2015 Oct 1;37(10):2267-74. doi: 10.1016/j.clinthera.2015.07.023
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
13 patients diagnosed with non-cardiac chest pain were randomly assigned to orally consume twice a day for 4 weeks either 5mg dronabinol capsules or placebo capsules. Metabolic parameters such as body mass index, various cholesterol levels, triglyceride level, plasma glucose level, insulin and leptin level, and high-sensitivity C-reactive protein level were assessed at the beginning and end of the...
Join the Conversation
Please Login or Join to leave comments.